Background: For women who have had a previous low transverse cesarean delivery, the decision to undergo a trial of labor after cesarean (TOLAC) or an elective repeat cesarean delivery (ERCD) has important clinical and economic ramifications. Objectives: To evaluate the cost-effectiveness of the alternative choices of a TOLAC and an ERCD for women with low-risk, singleton gestation pregnancies. Methods: We searched EMBASE, MEDLINE, CINAHL, Cochrane Library, EconLit, and the Cost-Effectiveness Analysis Registry with no language, publication, or date restrictions up until October 2015. Studies were included if they were primary research, compared a TOLAC with an ERCD, and provided information on the relative cost of the alternatives. Abstracts and partial economic evaluations were excluded. Results: Of 310 studies initially reviewed, 7 studies were included in the systematic review. In the base-case analyses, 4 studies concluded that TOLAC was dominant over ERCD, 1 study found ERCD to be dominant, and 2 studies found that although TOLAC was more costly, it offered more benefits and was thus cost-effective from a population perspective when considering societal willingness to pay for better outcomes. In sensitivity analyses, cost-effectiveness was found to be dependent on a high likelihood of TOLAC success, low risk of uterine rupture, and low relative cost of TOLAC compared with ERCD. Conclusions: For women who are likely to have a successful vaginal delivery, routine ERCD may result in excess morbidity and cost from a population perspective.
Introduction
As the most frequently performed surgical procedure in the United States [1] , cesarean deliveries accounted for 32.2% of nearly 4 million births in 2014 [2] -a substantial increase from 20% in 1996 and 5% in 1970 [3] . Although the optimum mode of delivery after a previous cesarean delivery is dependent on various individual characteristics and the indications for the primary cesarean birth [4, 5] , clinical consensus is that a trial of labor after cesarean (TOLAC) is generally a safe alternative to an elective repeat cesarean delivery (ERCD) for most women [6] . Despite these guidelines, more than 90% of women who have had a previous cesarean delivery have a repeat cesarean in subsequent pregnancies [7] . Although these women may avoid uterine rupture, they are increasingly susceptible to greater maternal morbidity than their successful TOLAC counterparts, especially across multiple cesareans [8] .
In addition to clinical consequences, the decision to undergo a TOLAC or an ERCD has important economic ramifications. The cost incurred by hospitals, and thus passed on to payers in the health system, is generally considered to be greater for an ERCD because of higher resource use and longer average hospital stays [9] . Nevertheless, because of the various types of costing methods, the estimated economic impact has varied by study. Although most studies have found cesarean births to be more costly than vaginal births when assessing payments made [10] [11] [12] , a few studies have reported that vaginal deliveries offer only a modest reduction in cost [13, 14] . Some, however, have found that cesarean deliveries may be equivalent to vaginal deliveries, or even cost saving, in terms of economic impact after accounting for variables such as oxytocin augmentation, epidural anesthesia, or failed trials of labor [15, 16] .
From a public health perspective, it is crucial to maximize health outcomes while stewarding constrained resources. Economic evaluations allow for the formal comparison of alternative interventions with simultaneous regard to their health effects, resource use, and costs [17] . The objective of this systematic review was to analyze the range and quality of studies that address the cost-effectiveness of the alternative choices of a TOLAC and an ERCD for women with a singleton gestation who have had a previous low transverse cesarean delivery.
Methods

Conduct of Systematic Review
We developed a systematic review protocol using the Preferred Reporting Items for Systematic review and Meta-Analysis for Protocols (PRISMA-P) [18, 19] and registered it in the PROSPERO database (CRD42015029177) [20] . In consultation with a librarian, we searched the databases EMBASE, MEDLINE, CINAHL, Cochrane Library, EconLit, and the Cost-Effectiveness Analysis Registry without language, publication, or date restrictions up until October 2015. Details of the search strategy are available in Appendix A. The reference lists of included articles were assessed for additional relevant studies.
Study Selection
Studies were included if they met the following criteria: 1) had to be primary research; 2) compared TOLAC versus ERCD; and 3) provided information on the relative cost of each course of action. One investigator screened all the abstracts of retrieved articles according to the inclusion criteria, erring toward inclusion in the case of uncertainty. Two investigators then assessed full-text articles that passed the initial screen, with disagreements on which articles to include resolved by discussion. Conference abstracts for which full-text articles were unavailable and partial economic evaluations, which comprise "cost analyses, cost-description studies and cost-outcome descriptions," were excluded [21] .
Data Extraction and Quality Assessment
Two investigators independently abstracted data from each article using the Guide to Community Preventive Services Economic Evaluation Abstraction Form [22, 23] and the recommendations of the Panel on Cost-Effectiveness in Health and Medicine [24] . The principal summary measures of interest were incremental cost-utility ratios (i.e., the additional cost per utility-a measure of both length of life and subjective level of well-being), cost-effectiveness ratios (i.e., the additional cost per unit of effect -identical units of an outcome or event such as death), or costbenefit ratios (i.e., the additional cost per benefit-in which effects of alternative interventions are expressed in monetary units) [21] . A validated quality assessment tool was considered [25] , but not used because there is a lack of consensus in the literature as to the ideal instrument for economic evaluations [26, 27] . We used the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist because it offers more precise guidance as to which components are essential. We scored studies on whether they completely satisfy (1), partially satisfy (0.5), or do not satisfy (0) each component, with a maximum score of 24 (Appendix B) [28] . The level of agreement was assessed with kappa statistics, and differences in CHEERS scores were resolved by discussion.
Costs
To make the studies comparable, all costs were adjusted to 2016 US dollars using purchasing power parities for the year of the data [29] and then adjusted for inflation using the medical care component of the Consumer Price Index [30] .
Results
Search Results and Quality Assessment
Database searches yielded 310 records, 224 of which were unique citations (Fig. 1) . Seven studies [31] [32] [33] [34] [35] [36] [37] met the inclusion and exclusion rubric for this systematic review (Table 1) . Six studies presented a cost-utility analysis [31] [32] [33] [34] [35] [36] , and one study presented a cost-effectiveness analysis [37] . Six of the studies [31, 32, [34] [35] [36] [37] were conducted in North America and one [33] in Europe. CHEERS scores ranged from 11 to 23, with most of the studies providing comprehensive information about their methods and results. The study by Chuang et al. [31] was an outlier in terms of its CHEERS score because of incomplete reporting on items such as study perspective, preference-based outcomes, and model assumptions; the other studies had scores ranging from 21 to 23. The inter-rater reliability for the raters was found to be κ ¼ 0.773 (95% confidence interval 0.649-0.897).
Study Characteristics
Decision modeling and analytic horizon
The included studies primarily defined their populations as being women who had one previous low transverse cesarean delivery and no contraindications to labor. All studies presented a decision tree comprising the decision node of a TOLAC versus an ERCD, with the TOLAC branch allowing for either a successful or failed trial of labor, and uterine rupture as a potential severe adverse event of TOLAC. Two studies [31, 33] used a short-term analytic horizon, whereby costs and consequences accrued in the immediate time period surrounding the index pregnancy. The remaining studies used long-term analytic horizons and reported discount rates for both costs and utilities, thus evaluating future costs and consequences in terms of their present value. Two studies [34, 37] allowed for the decision made in the index pregnancy to impact the outcomes and costs of future pregnancies by using a Markov model.
Study perspective
The study perspective, the viewpoint from which the costs are calculated (hospital, payer, or society), varied among the studies. Three studies [33, 36, 37] reported the payer's perspective-the insurance company or the government (in the case of Ireland)-as the entity responsible for paying for the costs. In these studies, cost components generally included short-term hospitalization costs (direct and indirect), professional fees, and long-term costs. Among the three studies [32, 34, 35 ] with a societal perspectivewhich considers the costs borne by the patient and is thus recommended by the Panel on Cost-Effectiveness in Health and Medicine-patient out-of-pocket costs and loss of employment productivity were added into calculations [24] . Chuang et al. [31] did not report the perspective taken, but it appears to be that of the hospital.
Utility inputs
The summary measures that were reported differed among the studies. The study by Grobman et al. [37] calculated the incremental cost of an ERCD over a TOLAC for one major neonatal adverse outcome (death or cerebral palsy). The other six studies assigned a utility value to the various delivery outcomes and complications. Chung et al. [32] used the Quality of Well-Being classification system [38] to derive utilities and were subsequently quoted in articles by Fawsitt et al. [33] and Gilbert et al. [34, 35] . Chuang et al. [31] used several studies that measured patient preference values with regard to labor and postpartum
complications. Wymer et al. [36] used utilities drawn from previously published cost-effectiveness analyses.
Outcome probability inputs
Although all studies assessed maternal outcomes (such as operative injury, endometritis, hysterectomy, and mortality) and most assessed infant outcomes, Chuang et al. [31] and Fawsitt et al. [33] did not include infant outcomes (such as cerebral palsy, hypoxic ischemic encephalopathy, and mortality) in their analyses (see Tables 2 and 3) .
Bias
Ideally, to compare a TOLAC with an ERCD without confounding factors influencing the outcomes, women would be randomized in a trial to one of the delivery approaches. Nevertheless, challenges with obtaining consent to assign mode of delivery make such a trial unlikely, especially given the large sample size that would be required to power the study. Thus, outcome probabilities for the decision trees in five of the studies [31] [32] [33] 36, 37] were extracted from published observational studies, in which women had a choice of delivery mode. Although both the studies of Gilbert et al. [34, 35] had the advantage of a large registry (the Cesarean Registry comprising 19 clinical centers by the Maternal-Fetal Medicine Units Network) from which to draw outcome probabilities, only one of the studies [35] was designed to address the lack of randomization by using propensity scores to balance observed and unobserved baseline covariates [39, 40] .
Synthesis of Results
Base-case analyses
When comparing an ERCD and a TOLAC on the two dimensions of effectiveness and cost, the ERCD could be dominant (less costly and more effective), dominated (more costly and less effective), less effective but also less costly, or provide additional effect but at an additional cost. In the latter two scenarios, society would need to determine whether it is willing to pay a premium for the additional benefit, thus determining the cost-effectiveness of the alternatives. Four studies [33] [34] [35] [36] (Table 4) found in their basecase analyses that ERCD was dominated by TOLAC. One study [31] found that ERCD dominated TOLAC, and two studies [32, 37] concluded that TOLAC was more cost-effective when considering societal preferences.
Among the latter three studies, Chuang et al. [31] reported in base-case calculations that ERCD provided additional utility at a lower cost when compared with TOLAC, but in their discussion concluded that the strategies were "more or less equivalent" when taking parameter uncertainties into account. Chung et al. [32] found that an ERCD would cost an additional $195,668 per quality-adjusted life-year (QALY) in 2016 US dollars, thus providing more utility than a TOLAC, but at a higher cost. Because the incremental cost-utility ratio of Chung et al. [32] was higher than a commonly used societal willingness-to-pay threshold of $50,000 per QALY, the authors concluded that a TOLAC was the cost-effective option when all model parameters were set at their most likely values. Even if Chung et al. [32] had used a higher threshold of $100,000 per QALY gained, TOLAC would have still been preferred by society. Grobman et al. [37] reported that averting one major adverse neonatal outcome (death or cerebral palsy) would require 1591 cesarean deliveries and come at a cost of $4.33 million in 2016 US dollars. Grobman et al. [37] ultimately concluded that routine ERCD would come at a high cost and result in an excess of maternal morbidity and mortality.
Future pregnancies were considered in three studies. Wymer et al. [36] compared successive delivery outcomes and determined that the benefits of a TOLAC accrue over multiple cesareans, with a decreasing incremental cost and increasing probability of cost-effectiveness. Grobman et al. [37] and Gilbert et al. [34] did not compare successive models but rather built the events over a woman's reproductive life into their base-case model and concluded qualitatively that the risks and costs associated with routine ERCD are potentially greater than societal willingness to pay. CHEERS, Consolidated Health Economic Evaluation Reporting Standards; NA, not applicable; QALYs, quality-adjusted life-years; SA, sensitivity analysis. * The CHEERS statement has a 24-item checklist. We assessed whether the studies completely satisfy (1), partially satisfy (0.5), or do not satisfy (0) each component, with a maximum score of 24.
Nevertheless, because none of the studies conducted heterogeneity analyses and two studies conducted short-term analyses that did not require the inclusion of discount rates, the total possible score for any study was 22 or 23. [31] (1999)
• 
Sensitivity analyses
To account for uncertainty in the model parameters, all studies conducted deterministic sensitivity analyses, varying the input values within their plausible ranges either individually or in conjunction with related variables. Threshold values were reported for sensitive variables that changed the preferred outcome when varied. There were several scenarios in which ERCD was the preferred strategy. First, if the probability of TOLAC success was low, the increased cost of an emergency cesarean delivery made the TOLAC attempt more costly. Although the heterogeneity in study methods make it impossible to summarize the cutoff value at which these scenario parameters changed the outcome conclusion, TOLAC was found to be cost-effective in univariate sensitivity analyses if the probability of TOLAC success was greater than 42% [35] , 46% [34] , 74% [32] , or 95% [31] , depending on the study. In the study reporting a 95% TOLAC success threshold, Chuang et al. [31] had assumed at baseline that a TOLAC was more expensive than an ERCD, making it an outlier among the studies.
Second, if the probability of uterine rupture was high, the potential morbidity associated with TOLAC made it less effective. Threshold values reported in the various studies were 3.1% [34] , 3.2% [32] , and 4.2% [35] . Because several studies found both the probability of TOLAC success and the probability of uterine rupture to be sensitive variables, bivariate sensitivity analyses were conducted by Gilbert et al. [34] to determine the joint impact of the variables. They found that when the probability of uterine rupture was set at 0%, 0.8%, 1.5%, and 3.0%, TOLAC was preferred if the probability of success was 40.0%, 47.2%, 53.6%, and 67.2% or more, respectively.
Third, if the cost of TOLAC was more than that of ERCD, the latter may be more cost-effective. Both the studies by Gilbert et al. [34, 35] and the study by Wymer et al. [36] found the costeffectiveness of TOLAC to be sensitive to the costs of TOLAC and ERCD. Because TOLAC offered more benefits than ERCD in those studies, it may be inferred that its cost could be slightly higher than ERCD and still be preferred, all else being equal. Bivariate sensitivity analyses on the costs were not performed, and thus it is not possible to determine how much excess cost TOLAC could incur before ERCD becomes more cost-effective in different scenarios.
Probabilistic sensitivity analyses were conducted in four studies [33] [34] [35] [36] using Monte-Carlo simulations whereby parameter values were drawn from within a distribution of possible values during each iteration of the model. TOLAC was the more cost-effective option under most assumptions, a result that was robust as probabilistic sensitivity analyses found TOLAC to be preferred between 64.4% of the time and 100% of the time across the different studies. Nevertheless, when disability resultant from stress urinary incontinence (SUI) was included in probabilistic sensitivity analyses, Gilbert et al. [34] found it to substantially impact ERCD preference over TOLAC, causing TOLAC to be preferred 7.3% of the time instead of 64.6% of the time. Chung et al. [32] on the other hand did not find SUI or fecal incontinence to be sensitive variables and the remaining studies either explicitly excluded SUI because of inconclusive literature on the subject or did not mention its potential impact.
Discussion
Main Findings
We conducted a comprehensive systematic review to summarize economic evaluations that compare a TOLAC with an ERCD for women with a singleton gestation who had a previous low transverse cesarean delivery. Six studies [32] [33] [34] [35] [36] [37] found TOLAC (neonatal model) of the time; with each subsequent vaginal delivery taken into consideration, the model was increasingly robust toward TOLAC ERCD, elective repeat cesarean delivery; ICER, incremental cost-effectiveness ratio; NA, not applicable; QALY, quality-adjusted life-year; SA, sensitivity analysis; SUI, stress urinary incontinence; TOLAC, trial of labor after cesarean. * For comparability between studies, incremental effectiveness and incremental cost per unit of effectiveness was calculated from the reported ICERs. Negative incremental effectiveness indicates that ERCD had decreased effectiveness relative to TOLAC in the base-case scenario. All costs were adjusted to 2016 US $ using purchasing power parities for the year of the data and then adjusting for inflation using the medical care component of the Consumer Price Index. † All cost-effectiveness decisions were reported on the basis of a willingness-to-pay threshold of $50,000. ‡ If base year of currency was not explicitly reported, we assumed year before publication; if currency was not explicitly reported, we guessed on the basis of the context. § For the Wymer et al. study, the cost and utilities from the maternal and neonatal models for the second delivery were summed up. to be either dominant or cost-effective under most assumptions. One study [31] found that ERCD was dominant in the base-case scenario, but concluded that on the basis of sensitivity analyses, TOLAC and ERCD were equivalent strategies. Thus, evidence suggests that a TOLAC is a cost-effective strategy for women with low-risk, singleton gestation pregnancies.
There are, however, several scenarios in which ERCD may be the preferred strategy. These include low likelihood of TOLAC success, high likelihood of uterine rupture, high cost of TOLAC relative to ERCD, and high likelihood of disutility resultant from SUI. The best evidence suggests that in the United States, an average of 74% of women who attempt a TOLAC deliver vaginally, with higher rates of success being reported in studies outside of the United States [8] . Furthermore, literature on symptomatic uterine rupture among women who had a previous low transverse cesarean incision has found that the risk varies between 0.3% and 1%, making TOLAC the preferred option unless a population opts for an induction of labor or has a high incidence of other risk factors for uterine rupture such as unfavorable cervical status at the time of admission, obesity, or an interpregnancy interval of 18 months or less [6, 8] . Thus, in most conditions, it is unlikely that the TOLAC success and uterine rupture rates would achieve the threshold values required to make ERCD more cost-effective. Only the study by Chuang et al. [31] considered TOLAC to have a higher cost at baseline relative to ERCD, and the literature is inconclusive as to the relative excess risk of SUI after a TOLAC. Thus, these factors did not feature greatly in the cost-effectiveness considerations of the included studies.
Progression of Evidence
When assessing the contribution of successive studies to the state of evidence, we found a progression from simple but representative short-term decision-analysis models to complex models that accounted for the long-term consequences of the index decision. Chuang et al. [31] (1999) constructed a decision tree comparing a TOLAC with an ERCD that streamlined all possible outcomes into being major, minor, or no complications, and performed basic deterministic sensitivity analyses. This was the first known study to conduct a full economic evaluation that simultaneously compared both costs and health outcomes of TOLAC versus ERCD. Grobman et al. [37] (2000) expanded the analytic horizon by extending the decision tree with Markov modeling, allowing for downstream reproductive decisions and outcomes to be impacted by the choice of a TOLAC or an ERCD. Their results, presented as cost-effectiveness estimates for the avoidance of one major neonatal outcome, were the first to describe the cost and outcome trade-offs associated with the alternative delivery options. Chung et al. [32] (2001) conducted the first comprehensive cost-utility analysis, providing two-way sensitivity analyses interpreted in light of a willingness-to-pay threshold and a societal perspective. All in all, these early studies found neither strategy to be dominant, with ERCD seeming to offer reduced adverse events but at significant cost.
In contrast, later studies all determined in their base-case scenarios that TOLAC was dominant compared with ERCD. Fawsitt et al. [33] (2013) conducted the first international economic evaluation, modeling considerations unique to the Irish health system, such as prevalent use of vacuum assistance during vaginal deliveries. In that setting, TOLAC was found to be dominant 100% of the time. Gilbert et al. conducted two studies [34, 35] , (2013) both of which incorporated patient opportunity costs. The studies differed in that one added to the literature by using a minimally biased cohort, whereas the other conducted a life-cycle Markov analysis; both conducted comprehensive sensitivity analyses confirming the robustness of their conclusion that TOLAC was cost-effective under a wide range of assumptions.
Wymer et al. [36] (2014) provided evidence that the morbidity and cost accruing from multiple cesarean deliveries further strengthened the argument for TOLAC in low-risk women who may choose to have future pregnancies. These results are particularly relevant considering that the risk of maternal complications such as placenta previa and accreta increases incrementally with an increased number of cesarean deliveries, resulting in elevated risk of poor maternal and neonatal outcomes [41, 42] . Conversely, having had any previous vaginal delivery, including vaginal birth after cesarean, increases the likelihood of future TOLAC success [43, 44] .
Strengths and Limitations
Although previous studies have reviewed economic evidence for a TOLAC versus an ERCD [45, 46] , we add to the literature by systematically summarizing and comparing the available evidence. This study has several notable limitations. Because the included studies primarily modeled women with low transverse uterine scars who had no contraindications to labor, the results are generalizable only to a profile of women with a higher TOLAC success likelihood and low risk of uterine rupture. Similarly, this study is limited by the bias inherent in the included studies because data on maternal and infant outcomes often have information only for the actual rather than the intended routes of delivery [8] . Only one of the reviewed studies addressed potential confounding resulting from the lack of randomization to a TOLAC or an ERCD by using propensity scores [35] . Another limitation is that although we tried to incorporate all evidence that met our inclusion and exclusion criteria, we are unable to assess the impact of reporting bias on our results. Finally, it should be noted that the studies by Chuang et al. [31] and Fawsitt et al. [33] assessed only short-term outcomes and did not include the impact of the TOLAC versus ERCD decision on neonatal outcomes. Although the usefulness of those studies may be limited by this omission, they still contributed valuable information for the purposes of this systematic review. In particular, the study by Fawsitt et al. [33] used a methodical bottom-up costing strategy that incorporated itemized resource use, labor duration, professional wages and benefits, and a range of costs including administrative, operational, and capital costs. It was the only study that explicitly modeled TOLAC as requiring more time spent in labor than ERCD. In spite of the fact that this led to higher staff costs for TOLAC, the study still found TOLAC to be dominant.
One challenge to uniformity of cost-effectiveness analyses in general is the variability in costing methods [47] . The true cost incurred by hospitals is difficult to ascertain because it requires a microcosting approach whereby all resources used are identified, measured, and valued [48] . These costs are seldom published or generalizable to other facilities. As a result, studies included in this systematic review may have used different sources for their cost inputs. To begin to address the issue of nonstandardization, one important source of costing data in the United States is the Healthcare Cost and Utilization Project, which converts hospital charges minus physician fees into costs on the basis of standard cost-tocharge ratios [9] . It should also be noted that this systematic review was unable to provide a summary estimate of the cost-effectiveness of an ERCD versus a TOLAC because there is at present no agreedupon method for pooling combined estimates, because resource use and costs are sensitive to variability across settings, and because the included studies were presented from different perspectives [21, 49] .
Comparison with Existing Literature
In 2003, the Agency for Healthcare Research and Quality published an evidence report on vaginal birth after cesarean deliveries that incorporated a review of the economic literature [45] . ( 2 0 1 7 ) 1 6 3 -1 7 3 The report found that at the time, only the study by Chung et al. [32] provided adequate evidence on the relative value of TOLAC and ERCD. It suggested that future studies improve upon the state of evidence by performing bivariate and probabilistic sensitivity analyses, incorporating the impact of the index decision on future pregnancies, and including patient opportunity costs. Later studies by Gilbert et al. [34, 35] , Fawsitt et al. [33] , and Wymer et al. [36] responded to all these calls for evidence.
A host of factors have influenced the rate of a TOLAC, which ranges from 28% to 83% across delivery centers [8] . Factors that influence the rate and success of a TOLAC include hospital characteristics such as volume [53] , policy [54] , practice patterns [55] , and rural/ urban location [56] as well as patient characteristics such as obesity [57] , obstetric history [58] , socioeconomic factors [59] , and stage of labor dystocia causing the primary cesarean delivery [60] . In particular, the fear of regional, hospital, and individual liability may be a driving factor for cesarean rates [50, 51] , because the adverse consequences of a uterine rupture may be seen as more imminently damaging from a risk-assessment standpoint when compared with the complications of an ERCD [52] . Although these considerations may avoid an individual serious adverse event, they may not lead to an optimum patient outcomes and use of health care resources on a population level.
Conclusions and Implications
This study lends support to the cost-effectiveness of a TOLAC when compared with an ERCD in most scenarios for low-risk women who have had one previous cesarean delivery. Thus, from a populationbased and economic perspective, decision makers and clinicians should seek to encourage a TOLAC for low-risk women. Nevertheless, patient preferences informed by education should continue to direct decisions on the planned mode of delivery. Future studies should assess the impact of heterogeneity in hospital and patient characteristics on cost-effectiveness estimates.
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